title: Characteristics of long-term live-donor renal allograft survivors.
abstract: OBJECTIVE
  Despite the high rate of rejection, allograft failure and patient mortality in the early years of renal allotransplantation, some patients have done-remarkably well. We report here on 62 renal transplant recipients out of 144 patients (43%) who had functioning grafts for more than 15 years (range 15-24 years).
  
  
  METHODS
  Demographic and follow-up data for patients fulfilling the criteria were reviewed. These patients include 43 males and 19 females, with a mean age at transplantation of 27.5 +/- 6.6 years (range 9-43 years), and mean donor age of 30 +/- 8.6 years. The donor source was 8 parents, 49 siblings and 5 unrelated. The main causes of end-stage renal disease were chronic pyelonephritis and chronic glomerulonephritis. Twenty-nine patients were treated with cyclosporine (CsA) while 33 patients were primarily immunosuppressed by steroids and azathioprine.
  
  
  RESULTS
  Acute rejection episodes occurred in 40 patients (64.3%), out of them 19 patients experienced two or more acute rejection episodes. Univariate analysis showed that recipient and donor age, HLA-DR matching, pre- and post-transplant hypertension, ATN, delayed diuresis and chronic allograft nephropathy are significant risk factors; while recipient age, delayed diuresis and post-transplant hypertension were still significant by multivariate analysis.
  
  
  CONCLUSIONS
  We concluded that renal transplantation, even in its earliest years and despite the numerous complications, has provided 15 or more years of near-normal life to patients with end-stage renal disease. Certain characteristics of long-term renal allograft survivors include young donor/recipient pairs, good DR matching with less pre- and post-transplantation prevalence of hypertension.
authors.affiliation: Urology and Nephrology Center, University of Mansoura, Mansoura, Egypt. amgadelbaz@ahram0505.net
authors.forename: Amgad E
authors.initials: AE
authors.lastname: El-Agroudy
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Bakr
authors.forename: Nabil A
authors.initials: NA
authors.lastname: Hassan
authors.forename: Amani M
authors.initials: AM
authors.lastname: Ismail
authors.forename: Bedeir
authors.initials: B
authors.lastname: Ali-El-Dein
authors.forename: Ahmed B
authors.initials: AB
authors.lastname: Shehab El-Dein
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Ghoneim
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation; D019520:Living Donors; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents